


Gujarat-based pharma company develops potential treatment for diabetic neuropathy

Asprius Lifesciences, a Gujarat-based pharmaceutical company, has developed a new treatment for diabetic neuropathy, a condition that causes nerve damage in the peripheral areas of the body. The company has filed a patent for the treatment, which is a fixed-dose combination (FDC) of two drugs.



Diabetic neuropathy is a common condition, affecting over 2% of the global population. It is caused by damage to the nerves that control sensation and movement in the hands and feet. Symptoms of diabetic neuropathy can include numbness, tingling, pain, and weakness in the extremities.



The company is currently conducting clinical trials to evaluate the safety and efficacy of the FDC. If the trials are successful, the company plans to launch the treatment in India in the coming year.

"We are excited about the potential of this new treatment to help people with diabetic neuropathy," said Vishal Zinzuwadia, Chairman & MD of Asprius Lifesciences.

Dr Sanjay Agrawal, the inventor of this formulation and Medical Director of the company added, "It is high time we addressed this prevalent condition, especially as Diabetic Neuropathy can cause damage to specific subdivisions of the nervous system."

Diabetic neuropathy is a serious condition that can have a significant impact on quality of life. The new treatment developed by Asprius Lifesciences offers hope for people with this condition, and it could help to improve their symptoms and reduce their risk of further complications.